Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, today ... In this role, Michelle will work with current and potential ... development of iLab products. Her main goal will be to ... scientific community by offering the most advanced, user-friendly, and high-impact ...
(Date:1/14/2014)... (PRWEB) January 13, 2014 Bob Hainsey, ... more than 20 years in the industry, has joined ... . Hainsey will serve as the society’s Science and ... Hainsey join SPIE as our Technology Strategist, further strengthening ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... turbine, miniaturized ,car jack, and micro-chainmail demonstrate the ... ultra-precision EFAB manufacturing technology, VAN NUYS, Calif., ... Design & Manufacturing West a set of,highly-miniaturized ,building ... to develop innovative new products. Water-powered,turbines just over ...
... SEATTLE, Dec. 18 Cell Therapeutics, Inc.,(CTI) ... met with and received,feedback from the rapporteur and ... (paclitaxel poliglumex,CT-2103). The feedback supports submission of the ... the first half of 2008 that CTI was ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today announced that ... Chief Financial Officer effective January 2, 2008., ... Vice President,of Finance for NextHop Technologies, Inc., a ... President of Finance and Chief,Financial Officer for InfoGear ...
Cached Biology Technology:Microfabrica Introduces Set of Miniature 'Building Blocks' for Minimally-Invasive Medical Devices 2Microfabrica Introduces Set of Miniature 'Building Blocks' for Minimally-Invasive Medical Devices 3Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule 2Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule 3Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule 4IRIDEX Announces James Mackaness Will Be Chief Financial Officer 2
(Date:4/20/2014)... Mothers give a newborn baby a gift of ... system. But antibiotics, used to fend off infection, ... leaving already-vulnerable premature babies more susceptible to dangerous ... neonatology researchers at The Children,s Hospital of Philadelphia ... revealing how gut microbes play a crucial role ...
(Date:4/18/2014)... scientists have used techniques like X-ray crystallography and nuclear ... the atomic structure of molecules, but such efforts have ... large quantities of a specific molecule and often in ... it all but impossible to peer into the structure ... problems may soon be a thing of the past. ...
(Date:4/18/2014)... soon as they,re planted may be good news for a ... the wild, a plant whose seeds sprouted at the first ... just an insurance policy against late frosts or unexpected dry ... too: Plants whose seeds put off sprouting until conditions ... a team of researchers working at the National Evolutionary Synthesis ...
Breaking Biology News(10 mins):Study of gut microbes, antibiotics: Clues to improving immunity in premature infants 2MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2
... of evolution of the two key characteristics that preceded flight: ... hulking meat-eating dinosaurs had to shrink in size and grow ... "We were really surprised to discover that the key ... of Paraves," said Mr Puttick of Bristol,s School of Earth ...
... have independently discovered that a single regulatory protein acts ... of male and female sexual forms (termed gametocytes) of ... biology with important implications for human health. The protein, ... that initiate the development of gametocytes -- the only ...
... , A molecule previously linked to lung injuries in ... role in microbial infections of the lung suffered by ... study led by San Diego State postdoctoral researcher Katrine ... be detected in higher concentrations in CF patients than ...
Cached Biology News:New insights into the origin of birds 2A key protein is discovered as essential for malaria parasite transmission to mosquitos 2A key protein is discovered as essential for malaria parasite transmission to mosquitos 3A key protein is discovered as essential for malaria parasite transmission to mosquitos 4A key protein is discovered as essential for malaria parasite transmission to mosquitos 5Is a 'buttery' molecule behind cystic fibrosis flare-ups? 2Is a 'buttery' molecule behind cystic fibrosis flare-ups? 3
... GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 H ... 6 ,M.W.= 408.63 ,Assay: Greater ... in DMF) ,Biological Activity: Blue color ... Analysis: Agrees with theoretical values ,Thin ...
BD IMagnet 1 each...
... A.P. Johnstone and M.W. Turner ... strategies and methods used in the ... of antibodies in immunoassays, the standardisation ... ELISA techniques including amplification systems, enzyme ...
MitoScreen (JC-1) Kit , 100 tests Consult technical datasheet for details....
Biology Products: